Breast Cancer

Trastuzumab monotherapy was not linked to surgical complications among patients with breast cancer undergoing reconstruction after a mastectomy.

A byproduct of cholesterol metabolism may fuel the spread of solid tumors.

Exposure to many chemicals, including gasoline, can heighten the risk of developing breast cancer.

New discovery about EGFR signaling may prevent cancer cells from spreading.

The mechanisms of BRCA mutations are still largely unknown.

Mammography plays an important role in breast cancer detection.

Early detection is crucial for breast cancer survival.

Top news of the day from across the healthcare landscape.

Top news of the day from across the healthcare landscape.

Mastectomy rates increased after actress Angelia Jolie announced her procedure.

Mass spectrometry device rapidly identifies molecular profile of cancerous tissue.

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

Gadolinium-containing imaging agent could improve breast cancer survival.

Pertuzumab-based regimen shows promise treating adjuvant treatment of HER2-positive early breast cancer.

Genentech is seeking approval for Perjeta used in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

Abemaciclib treats adults with hormone receptor-positive, human epidemical growth factor receptor-negative advanced or metastatic breast cancer that progressed after endocrine therapy.

Verzenio can be administered as a stand-alone treatment to patients previously treated with endocrine therapy and chemotherapy.

Officials with the FDA have approved abemaciclib (Verzenio, Eli Lilly), for the treatment of adults with certain advanced or metastatic breast cancer.

Top news of the week from Specialty Pharmacy Times.

Many researchers are interested in looking at FDA-approved drugs that could potentially be repositioned for use in cancer treatment.

Certain adjuvant chemotherapy regimens may lead to long-lasting peripheral neuropathy in breast cancer survivors.

Adjuvant endocrine therapy can prevent cancer recurrence but can result in painful side effects.

Mvasi is indicated to treat adult patients with certain types of colorectal, lung, brain, kidney, and cervical cancers.

Bevacizumab-awwb, a biosimilar to Avastin, approved to treat several cancer types.

Nerlynx is indicated to treat early-stage HER2-positive breast cancer following trastuzumab-based therapy.

Tumor biology and size should guide breast cancer treatment.

Investigational trastuzumab biosimilar shows promise as potential lower cost treatment option to Herceptin for breast cancer and gastric cancer.